[18F]-AraG PET Imaging in LA HNSCC
Part of paid clinical trials in Indianapolis, Indiana.
- Sponsor
- Indiana University
- Study ID
- NCT07168785
- Phase
- EARLY_PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Locally Advanced Head and Neck Squamous Cell Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- [18F]-AraG radiotracer — DRUG\[18F\]-AraG radiotracer, which occurs on the first and sixteenth day of treatment.
- Chemotherapy — DRUGConcurrent chemoradiotherapy (CRT) with weekly doses of cisplatin.
- Radiotherapy — DEVICEConcurrent chemoradiotherapy (CRT) of 70Gy of radiation dose in 33 fractions.
Study Details
This study will use \[18F\]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for treatment.
Key Dates
- Start date
- Oct 1, 2025
- Status verified
- Sep 2025
- Primary completion
- Jun 30, 2027
- Completion
- Oct 31, 2027
Study Design
- Enrollment
- 5 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: [18F]-AraG PET/CT scan\[18F\]-AraG PET/CT scans to be performed according to the institution's standard of operation, which occurs on the first and sixteenth day of treatment.
Primary Outcome Measure
[18F]-AraG PET/CT uptake and infiltrating cytotoxic T-cell expression. [ Time Frame: Week 1 and Week 16 ]
Central Contacts
- Kathryn I Lauer(317) 962-8969
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Indiana University | Indianapolis | Indiana | 46202 | Mark Langer, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Indianapolis, IN
By research site
Related Studies
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPHASE1 · Recruiting · Exelixis · Phoenix, Arizona
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerPHASE1 · Recruiting · National Cancer Institute (NCI) · Tampa, Florida
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Mayo Clinic · Jacksonville, Florida
- Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckPHASE1 · Enrolling By Invitation · Krzysztof Misiukiewicz · New York, New York